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ABSTRACT
Glutathione S-transferases (GST) are antioxidant enzymes that play an important role in the cellular detoxification and
excretion of environmental pollutants including heavy metals. GST mu (GSTM1) and G theta (GSTT1) are known to be
highly polymorphic and homozygous deletions of these genes result in the lack of enzyme activity and when combined
with decreased levels of antioxidants, they have been associated with the Autism Spectrum Disorder (ASD). This
preliminary study was performed to investigate the role of GSTM1 and GSTT1 polymorphisms as risk factors of ASD
associated with GST activity and phenotype expression. Fifty one ASD patients and 45 controls were recruited for
GSTM1 and GSTT1 genotyping while 6 ASD patients and 8 controls were assessed for GST activity. The results showed
no significant differences in frequencies of GSTM1 null, GSTT1 null and combination both genotype between ASD
patients and controls. However the mean erythrocyte GST activity in ASD is significantly decreased compared with
controls (p = 0.043). The mean erythrocyte GST activity is lower in the severely autistic group compare to the mild to
moderately autistic group, although it was not statistically significant. Further investigations are needed with a bigger
sample size, analyzing multiple GST genes and GST activity determination to find out the gene susceptibility of ASD and
factors that contribute to the phenotype expression of ASD.
INTRODUCTION
Autism spectrum disorder (ASD) is a neurodevelopmental
disorder characterized by qualitative impairments in the
development of social and communication skills which is
often accompanied by stereotyped and restricted patterns
of interests and behavior with the onset of impairment
before the age of three. ASD includes the diagnostic
categories of autistic disorder, pervasive developmental
disorder not otherwise specified (PDD-NOS) and
Asperger’s syndrome (1). Childhood Autism Rating Scale
(CARS) is often used for evaluating the child’s body
movements, adaptation to change, listening response,
verbal communication, and relationship to people in
children over 2 years of age. The child’s behavior is rated
on a scale based on deviation from the typical behavior of
children of the same age (2).
Epidemiological studies demonstrate that the
prevalence of autism has increased in recent years (3). It is
currently estimated that autism affects as many as 1 out of
150 children (67 per 10,000) in the United States and occurs
four times as frequently in males as females (4). Overall, the
incidence of ASD in children age 0 to 4 years was 5.49 per
10 000 for Chinese children in Hong Kong (5) while the
incidence of was estimated to be 4.3 to 5.5 per 10 000 in
Australia (6) and as high as 27.2 per 10 000 children in
Japan (7).
Investigators suggested that ASD may result from the
interaction between genetic and environmental factors, with
oxidative stress as a mechanism linking these risk factors
(8). There is evidence supporting the role of oxidative stress
in autism (9) that affect brain development during gestation
or possibly after gestation, contributing to expression of
autism (10). Studies have shown that in autism, the plasma
total gluthatione (tGSH) levels were lower, while levels of
oxidized GSH (GSSG) were elevated and the ratios of tGSH
to GSSG were low (8, 11), which results in impaired ability
to excrete metals including mercury for which GSH act as
the major detoxification compound in the body (12).
Glutathione S-transferases (GST) are antioxidant
enzymes that play important roles in the cellular
detoxification, excretion of environmental pollutants as well
as protection against oxidative stress by their ability to
conjugate GSH with compounds containing an electrophilic
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center (13). The electrophilic functional group for
conjugation reactions can be provided by a carbon, a
nitrogen, or a sulfur atom (14-16). These enzymes detoxify
a broad range of substances including carcinogens,
environmental toxins, and drugs. At least seven distinct
classes have been identified: alpha (α), mu (µ), pi (π), sigma
(σ), theta (τ), kappa (κ), and zeta (ξ). This classification is
according to the substrate specificity, chemical affinity,
structure, amino acid sequence and kinetic behavior of the
enzymes (14).
GST mu (GSTM1) and GST theta (GSTT1) are known
to be highly polymorphic and have been investigated in
relation to various types of diseases, including diabetes
mellitus, hypertension, stroke, Parkinson’s disease,
rheumatoid arthritis and some types of cancer (16-20).
Subjects with at least one functional allele are designated
as GSTM1 or GSTT1 positive (14) but homozygous
deletions of these genes, referred to as GSTM1 null
(GSTM1-/-) and GSTT1 null (GSTT1-/-) respectively, result
in reduced enzyme activity (21). Two Korean case-control
studies found frequencies of 53% and 56% for the GSTM1
deletion genotype (22) while the Indian population showed
a lower percentage of GSTM1-/- frequency (30.4-35.4%)
when compared to other Asian and Caucasian populations
which was reported in the range of 49-53.8% (23).
Population-based study has reported that the frequency
among Caucasians in the United States of America ranged
from 48%-57% (22). The prevalence of the GSTT1-/-
genotype has been shown to be 11% in European and
North American Caucasians (24-27), while in Asia the
prevalence is much higher, which is 49% in Shanghai, 47%
in Taiwan and 44% in Japan (28-30).
The association of GSTM1-/- with autism has been
reported in a previous study (31) which showed an
increased genotype relative risk near 2 for the homozygous
GSTM null genotype and autism. Meanwhile, a recent study
with an autism animal model using GSTM1 knockout mice
that were given valproic acid (VPA) treatment (which is
known to cause autism-like behavioral deficits) showed
higher rate of neuronal cell apoptosis compared to wild-
type controls (32). VPA administration during pregnancy
may result in fetal valproate syndrome which has features
similar to autism and rodents exposed in utero to VPA
showed both cellular damage and behavioral deficit that
are analogous to the autism phenotype (33). The absence
of the GSTM1 gene, resulting in impaired enzyme activity,
is believed to lead to failure of individuals with autism to
detoxify xenobiotics, including heavy metals such as
mercury (Hg). Hg when coupled with decreased levels of
antioxidants (low glutathione and antioxidant enzymes),
leads to the increased production of free radicals which
cause an increase in lipid peroxidation, protein oxidation,
and DNA oxidation that finally leads to increased oxidative
stress. Oxidative stress is associated with impaired neuronal
development, increased inflammatory response, impaired
energy production, cell death and decreased synaptic
efficiency. These combined effects contribute to the
phenotypic presentation of ASD (11). Therefore this
preliminary study was conducted to investigate the role of
GSTM1 and GSTT1 polymorphism as risk factor of ASD,
the association with GST activity and phenotype expression
in a cohort of Indonesian ASD patients.
MATERIALS AND METHODS
SUBJECTS
This was a case control study with a total of 96 subjects
comprising of 51 Autism Spectrum Disorder subjects from
the Special Need and Autism School and 45 unrelated
healthy subjects from the public schools in Semarang and
Solo, Indonesia. All the subjects for the study were aged
between 2- 18 years old. Diagnosis of ASD was according
to Diagnosis and Statistical Manual of Mental Disorders,
fourth edition (DSM IV) and phenotype expression of ASD
was determined using CARS. This study was approved by
the institutional review committee from the Medical Faculty
Diponegoro University and the Ethics Committee of Dr.
Kariadi Hospital Semarang, Indonesia. The study was
conducted with informed consent from all of the subjects’
parents. The analysis was done at the Centre for Biomedical
Research (CEBIOR) in the Medical Faculty Diponegoro
University, Indonesia and the UKM Medical Molecular
Biology Institute (UMBI), Universiti Kebangsaan Malaysia.
GENOTYPING
Venous blood samples were collected from patients and
controls in EDTA tubes. Genomic DNA was extracted from
peripheral blood leukocytes using the salting-out method
(34). The genotype of GSTM1 and GSTT1 genes in the
subjects were determined using a multiplex PCR technique
with the co-amplification of β-globin gene as positive internal
control. Primers pairs used in this study were: GSTM1 gene
(forward primer 5’-TCTGGGGAGGTTTGTTTTCA-3’ and
reverse primer 5’ TCT CCAAAATGTCCACACGA-3’),
GSTT1 gene (forward primer 5’-TTCCTTACT
GGTCCTCACATCTC-3’ and reverse primer 5’-
TCACCGGATCATGGCCAGCA-3), β-globin gene (forward
primer 5’-GAGTCAAGGCTGAGAGATGCAGGA-3’ and
reverse primer 5’-CAATGTATCATGCCTCTT TGCACC-3’).
The multiplex PCR was performed in a 25 µl reaction
volume containing 30-50 ng of DNA, 12.5 µl HotStarTaq
Master Mix (Qiagen) which contained 1.25 units of
HotStarTaq DNA Polymerase, 1x PCR Buffer, 100 µM of
each dNTP and 0.75 mM of MgCl2. The final concentration
for each primer is 0.2 µM.
The PCR conditions for GSTM1 gene was performed
with an initial denaturation 95°C for 4 minutes, followed by
35 cycles with denaturation at 95°C for 1 minute, annealing
at 50°C and extension at 72°C for 2 minutes with final
extension at 72°C for 10 minutes. The PCR conditions for
GSTT1 gene utilized the same with protocol above except
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that the annealing temperature was changed to 61°C. A
PCR product of 625 bp denotes the presence of GSTM1, a
product of 459 bp denotes the presence of GSTT1 while a
product of 850 bp denotes the internal control. The presence
of GSTM1 and GSTT1 gene band was interpreted as GSTM1
and GSTT1 positive gene while the absence of GSTM1
and GSTT1 gene band was interpreted as GSTM1-/- and
GSTT1-/-.
GLUTATHIONE S-TRANSFERASE ACTIVITY
Blood samples were separated to 4 layers by lymphoprep.
Briefly, the red blood cells (RBC) were lysed in equal
volumes of ice-cold double distilled water and then
centrifuged at 10,000 g for 15 minutes at 4°C. The
supernatant was collected for the glutathione-s transferase
(GST) assay.
GST activity was determined using Glutathione S-
Transferase Assay Kit (Cayman, USA) by measuring the
conjugation of 1-chloro-2,4-dinitrobenzene (CDNB) with
reduced GSH. The GST assay was performed according to
assay protocol provided. Briefly, 170 µl of assay buffer and
20 µl of GSH were added to the non-enzymatic wells. In the
positive control wells, 150 µl of assay buffer, 20 µl of
glutathione and 20 µl of diluted GST (control) were added
together. For the sample wells, 150 µl of assay buffer, 20 µl
of glutathione and 20 µl of sample were added. The
reactions were initiated by adding 10 µl of CDNB to all of
the wells. The absorbance was read once every minute at
340 nm using a plate reader to obtain values at 8 time points.
GST activity in nmol/min/ml was calculated with the CDNB
extinction coefficient at 340 nm as 0.00503 µM-1. One unit
of enzyme will conjugate 1.0 nmol of CDNB with reduced
glutathione per minute at 25°C.
STATISTICAL ANALYSIS
Statistical analysis was carried out using SPSS (version
16.0). The data were reported as mean + SD. Chi-square
test was used to calculate the differences in genotype
prevalence and association between case and control
groups. Association between GST activity and phenotype
expression of ASD, case-control group and genotype was
analysed using Independent Samples T test and Mann-
Whitney U test if the data is not normally distributed.
Additionally, analysis between GST activity and CARS
score was analysed by regression. The Odds Ratio (OR)
and its 95% Confidence Interval (CI) were used to illustrate
the association. All of the tests were two sided and p value
< 0.05 was considered statistically significant.
RESULTS
Table 1 showed the frequency of the GSTM1 and GSTT1
genotypes in ASD and control group. The frequency of
GSTM1-/- (11.8%) in ASD was higher compared to the
control group (6.7%) but the difference was not statistically
significant. The frequency of GSTT1-/- genotype (39.2%)
was also higher among ASD patients compared to the
control group (31.1%) but there was no statistically
significant difference. In addition, the combination of
GSTM1-/-/ GSTT1-/- genotype was also not significant
between cases and controls [refer Table 2]. The phenotype
expression of ASD which were represented by CARS, were
divided into two groups: mild to moderately autistic and
severely autistic. We found no significant difference in the
distribution of GSTM1-/-, GSTT1-/-as well as GSTM1-/-/
GSTT1-/- genotype between the CARS score of mild to
moderately autistic and severely autistic [refer Table 2].
There was no significant difference for the mean
erythrocyte GST activity between GSTM1-/-, GSTT1-/- as
well as GSTM1-/-/ GSTT1-/- genotype respectively compared
to the controls. Table 3 showed that the mean erythrocyte
GST activity in ASD was significantly lower (0.374 ± 0.262
nmol/min/ml) compared with controls (1.486 ± 0.262 nmol/
min/ml). Whereas in the severely autistic, the mean
erythrocyte GST activity was lower (0.259 ± 0.037) compared
with mild to moderately autistic (0.432 ± 0.317) , but this
difference is not significant. The association of GST activity
with CARS score was also not significant (p = 0.089).
DISCUSSION
Autism spectrum disorder is a complex and multifactorial
disease, which leads to the difficulty of identifying
significant risk factors. Autism may result from a
Table 1. Frequency of GSTM1 and GSTT1 genotype in ASD patients and control group
GSTM1-/- Wild type Total GSTT1-/- Wild type Total
N % N % N % N % N % N %
Group
a. ASD 6 11.8 45 88.2 51 100 20 39.2 31 60.8 51 100
b. Control 3 6.7 42 93.3 45 100 14 31.1 31 68.9 45 100
CARS
a. Mild to moderately autistic 2 11.1 16 88.9 18 100 8 44.4 10 55.6 18 100
b. Severely autistic 4 12.9 27 87.1 31 100 10 32.3 21 67.7 31 100
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Table 3. Mean erythrocyte GST activity in ASD patients and control group. * Denotes to P < 0.05 for ASD compared to
wild-type controls
GST activity
Mean (nmol/min/ml) 95% CI p
Group
a. ASD 0.374 ± 0.262 0.164 - 0.584 0.043*
b. Control 1.486 ± 1.269 0.607 - 2.365
CARS
a. Mild to moderately autistic 0.432 ± 0.317 0.121 - 0.743 0.509
b. Severely autistic 0.259 ± 0.037 0.207 - 0.311
CARS score 24.990 - 47.410 0.089
combination of genetic susceptibility via the reduced ability
to remove metals including mercury or other neurotoxins
from the system, and environmental exposure (35-37).
Several genes have been reported associated with autism
including genes involved in methionine transmethylation
and transsulfuration pathways (8). Polymorphisms
of Reduced Folate Carrier I (RFC1) gene,
Methylenetetrahydrofolate Reductase (MTHFR),
Transcobalamin II (TCN2), Catechol-O-methyltransferase
(COMT) and Glutathione S-transferase mu 1 (GSTM1) have
all been shown to be significantly increased among autistic
children compared to controls (31, 38).
In the present study, we found that the frequency of
GSTM1-/- genotype in the control group was 6.7%, which
was quite different from the previous study in the Indonesian
population in Jakarta which reported a frequency of 55.6%
(39). Geographical and ethnic variations in the distribution
of GSTM1-/- and GSTT1-/- genotype frequencies has been
shown different ethnic groups in India (40) and this may
explain the difference in the frequency of GSTM-/- shown in
this study. Indonesia is a huge archipelago of islands with
many sub-ethnic groups from various regions and hence
could explain the wide difference in the frequency. The
frequency shown in our study is much lower than in the
Caucasian population (42-60%) and other Asians
population, including Japan (47.9%), South Korea (52.2%)
and Singapore (56.2%) (41). Meanwhile, our study showed
that the frequency of the GSTT1-/- genotype in the control
group was 31.1%, which is similar with Japan (35.3%), but
was lower than the previous study in Indonesia (41.4%)
(39), South Korea (51.5%) and Singapore (51.9%) (41).
However the GSTT1-/- frequency was higher compared to
the Europeans (22%) and the African-Americans (21%) (42).
Steven Buyske et al. (2006) reported a significant
association of the homozygous GSTM1 deletion genotype
with autism (p = 0.028) in their study involving 54 complete
case-parent trios and 172 controls, but our study did not
show similar association (31). Their study showed a high
frequency of the GSTM1-/- genotype, 69% compared to the
11.8% found in our study, which may explain for the lack of
association of the GSTM1 null genotype with autism. Our
study revealed that there is no significant association
between GSTM1-/- and GSTT1-/- gene with ASD, although
the distribution of these genes among our ASD patients
was higher than controls . The GSTM1-/-/ GSTT1-/- genotype
also did not contribute to ASD risk in our study population.
Our study also looked at the association between the
erythrocyte GST activity among ASD patients and control
groups as well the association between GST activity and
phenotype expression of ASD. Our study showed lower
GST activity in the GSTM1-/- and GSTT1-/- genotype groups
compared to the control group which was in concordance
to a recent study involving ischemic stroke patients,
although the difference was not significant (43). According
Table 2. Odd ratios (OR) and p value of GSTM1-/-, GSTT1-/- and GSTM1-/- / GSTT1-/- genotypes in association with groups and
phenotype expression. All results were not statistically significant
GSTM1-/- GSTT1-/- GSTM1-/-/GSTT1-/-
OR 95% CI p OR 95% CI p p
Group
a. ASD 0.536 0.126 - 2.280 0.495 0.700 0.301 - 1.630 0.407 0.299
b. Control
CARS
a. Mild to moderately autistic 0.844 0.139 - 5.138 1.000 1.680 0.508 - 5.558 0.394 0.667
b. Severely autistic
CARS score 0.317 0.157 0.476
GST activity 0.770 0.180 0.377
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to previous studies, there was no association between
GSTM1-/- and reduced erythrocyte GST activity observed
among Chinese patients, but combined GSTP1-/-/
GSTM1-/- genotype resulted in significantly reduced GST
activity (44). Another study in India showed that diabetes
mellitus patients with double GSTT1-/- and GSTM1-/-
genotypes have significantly low GST activity as compared
to other genotypic groups (45). Studies among Caucasian
patients and controls groups showed that those with
double GSTT1-/-/ GSTM1-/- genotypes had the lowest serum
total GST activities (22, 25-27).
The difference in our results compared with others
studies could be due to the fact that this study was
conducted in a different race and population. Another
explanation for the differences is that GST enzymes have a
broad substrate overlap, therefore decreased in expression
level of one GST may be compensated by increased
expression of another isoform (46). Therefore, this
preliminary study needs further investigations with
increased sample size, full genotyping of the GST isoforms
and GST activity determination, to explore further the
genetic susceptibility of ASD and factors that contribute
to the phenotype expression of ASD.
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